Summary
Our overarching hypothesis is that technical standardization of a unique advanced MRI technique using combined DCE and DSC MRI and the use of a standardize post-processing algorithm will allow validation of imaging biomarkers to improve assessment of the diagnosis, prognosis, and therapeutic response of different CNS diseases including brain tumors, stroke and neurodegenerative diseases. This will overcome current difficulties in comparison of DCE and DSC data from multiple institutions and also promote widespread clinical use.
Scope
The SAPP study comprises MRI perfusion analysis of image data from single site investigator initiated (IIS) sub studies (listed below), with each sub protocol using at least for one of the planned perfusion studies Gadobutrol (Gadovist®) as contrast media. The acquisition of the MRI scans should be done using defined and standardized image guidelines to ensure minimal variability.
Sub-Studies
The Ottawa Hospital, Canada
PI Dr. Thanh Binh Nguyen
Study Title: Evaluation of MR T1-weighted and T2-weighted perfusion imaging at 3T in the diagnosis of patients with glioma
Uppsala University Hospital, Sweden
PI Dr. Elna-Marie Larsson
Study Title: Perfusion MRI for evaluation of therapy response in malignant glioma
Universitätsklinikum Erlangen, Germany
PI Dr. Arnd Dörfler
Study Title: Intraindividual comparison of magnetic resonance perfusion imaging and magnetic resonance angiography in cerebrovascular patients
Universitätsklinikum Erlangen, Germany
PI Dr. Arnd Dörfler
Study Title: Classification and secondary prevention of dementia: role of Gadobutrol enhanced dynamic susceptibility MR perfusion
University of Southern California, USA
PI Dr. Meng Law
Study Title: Dynamic Contrast Enhanced Steady State T1-weighted Perfusion MRI (DCE- MRI): Characterization of Intracranial lesions comparing MR contrast agents with different T1 relaxivity
Perfusion will be analysed using several perfusion software systems in order to compare and discuss possibly different results.